Trial reports are written as they would be for medical papers, journals, etc and not to the lowest common denominator. thereby lies the problem. Traders don't get this. Investors generally do IMO. All in all, the report was positive in that there was a significant response in pain scores in all groups even though that resulted in no significant difference among groups, which caused confusion.
IMO, the MRI/CT results are all that matter because improvements in joint structure&infammation would correlate with pain score, which by itself would be highly subjective and would certainly not justify reimbursement; meaning, the OA trials would be a worthless endeavor. Should I add "another?" That said, I remain positive on the overall results of ADRC treatment.